189 related articles for article (PubMed ID: 21919613)
1. Protecting the initial site of viral entry: an alternative HIV vaccine target.
Lopalco L; Bomsel M
Expert Rev Vaccines; 2011 Sep; 10(9):1253-6. PubMed ID: 21919613
[No Abstract] [Full Text] [Related]
2. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract.
Hervouet C; Luci C; Cuburu N; Cremel M; Bekri S; Vimeux L; Marañon C; Czerkinsky C; Hosmalin A; Anjuère F
Vaccine; 2010 Aug; 28(34):5582-90. PubMed ID: 20600505
[TBL] [Abstract][Full Text] [Related]
3. Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form.
Pattani A; McKay PF; Curran RM; McCaffrey J; Gupta PN; Lowry D; Kett VL; Shattock RJ; McCarthy HO; Malcolm RK
Vaccine; 2012 Apr; 30(17):2778-85. PubMed ID: 22361120
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
[TBL] [Abstract][Full Text] [Related]
5. Circular CCR5 peptide conjugates and uses thereof (WO2008074895).
Sommerfelt MA
Expert Opin Ther Pat; 2009 Sep; 19(9):1323-8. PubMed ID: 19456281
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immunity, HIV transmission, and AIDS.
Miller CJ; McGhee JR; Gardner MB
Lab Invest; 1993 Feb; 68(2):129-45. PubMed ID: 8441249
[No Abstract] [Full Text] [Related]
7. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
Belyakov IM; Ahlers JD
Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.
Leroux-Roels G; Maes C; Clement F; van Engelenburg F; van den Dobbelsteen M; Adler M; Amacker M; Lopalco L; Bomsel M; Chalifour A; Fleury S
PLoS One; 2013; 8(2):e55438. PubMed ID: 23437055
[TBL] [Abstract][Full Text] [Related]
9. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus.
Mestecky J; Kutteh WH; Jackson S
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S11-20. PubMed ID: 7865284
[TBL] [Abstract][Full Text] [Related]
10. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
Bomsel M; Tudor D; Drillet AS; Alfsen A; Ganor Y; Roger MG; Mouz N; Amacker M; Chalifour A; Diomede L; Devillier G; Cong Z; Wei Q; Gao H; Qin C; Yang GB; Zurbriggen R; Lopalco L; Fleury S
Immunity; 2011 Feb; 34(2):269-80. PubMed ID: 21315623
[TBL] [Abstract][Full Text] [Related]
11. Female genital tract immunity: distinct immunological challenges for vaccine development.
Naz RK
J Reprod Immunol; 2012 Jan; 93(1):1-8. PubMed ID: 22154945
[TBL] [Abstract][Full Text] [Related]
12. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
13. Humoral immunity to HIV, SIV, and SHIV.
Haigwood NL; Zolla-Pazner S
AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
[No Abstract] [Full Text] [Related]
14. Mucosally-targeted HIV-1 vaccines.
Wegmann F
Hum Vaccin; 2011 Sep; 7(9):982-5. PubMed ID: 21892008
[No Abstract] [Full Text] [Related]
15. Mucosal approaches to HIV vaccine development.
Forrest BD
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1523-5. PubMed ID: 1466996
[No Abstract] [Full Text] [Related]
16. Inductive/effector mechanisms for humoral immunity at mucosal sites.
Wright PF
Am J Reprod Immunol; 2011 Mar; 65(3):248-52. PubMed ID: 21223423
[TBL] [Abstract][Full Text] [Related]
17. Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.
Mestecky J; Jackson S
J Clin Immunol; 1994 Sep; 14(5):259-72. PubMed ID: 7814455
[No Abstract] [Full Text] [Related]
18. Progress and obstacles in the development of an AIDS vaccine.
Letvin NL
Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
[TBL] [Abstract][Full Text] [Related]
19. Induction of innate immune responses in the female genital tract: friend or foe of HIV-1 infection?
Firoz Mian M; Ashkar AA
Am J Reprod Immunol; 2011 Mar; 65(3):344-51. PubMed ID: 21223417
[TBL] [Abstract][Full Text] [Related]
20. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
